慢性炎症性脱髄性多発ニューロパシー(CIDP)治療薬の世界市場:インサイト・疫学・市場予測

◆英語タイトル:Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Market Insight, Epidemiology and Market Forecast -2030
◆商品コード:DELV20JU030
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年5月
◆ページ数:211
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(30名様閲覧)USD6,950 ⇒換算¥729,750見積依頼/購入/質問フォーム
Three UserUSD10,425 ⇒換算¥1,094,625見積依頼/購入/質問フォーム
Site LicenseUSD13,900 ⇒換算¥1,459,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted CIDP symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder. It is an acquired peripheral neuropathy due to an autoimmune attack of peripheral nerve myelin. Myelin is the main target of the condition, in which patients present with weakness, numbness, and sensory ataxia (symptoms of large myelinated fiber dysfunction). A great deal of evidence, such as the finding of inflammation at the site of the lesion, response to immunomodulatory treatment and possibly the presence of autoantibodies against myelin antigens. The inflammation of the peripheral nervous system damages the myelin sheaths that insulate nerve fibers. CIDP usually spares the nerves that supply muscles of respiration and the autonomic nerves that control the bladder, bowel, and circulation. The disorder sometimes also called chronic relapsing polyneuropathy.

The disease often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. It can occur at any age and in both genders, CIDP is more common in young adults, and men more so than women. This condition is treatable for relatively long periods (months to years) in the majority of patients. CIDP usually presents in the “classical” form as the symmetrical disorder with proximal and distal weakness but also can manifest as a variety of other subtypes that can be multifocal or selectively involve sensory or motor nerve fibers.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Disease Understanding and Treatment Algorithm
It covers the details of conventional and current medical therapies and diagnosis available in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report gives a thorough understanding of CIDP symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides CIDP symptoms of treatment algorithms and treatment guidelines for CIDP symptoms in the US, Europe, and Japan.

The EFNS/PNS diagnostic criteria can address most of the diagnostic pitfalls and able to distinguish the different sub-types. According to EFNS/PNS guidelines, misdiagnosis is common in CIDP, especially in the atypical subtype. Electrophysiologic testing, the sensitivity of which is improved by testing more than 4 nerves, is necessary to confirm the diagnosis. The testing of 3 limbs may improve the diagnostic certainty of electrophysiologic testing. High-resolution ultrasound is a readily available tool that can be used at the bedside. Recent study results have demonstrated the potential utility of measuring abnormal nerve enlargement, both in the brachial plexus and proximal median nerve segments in the arm, with high-resolution ultrasound in the differential diagnosis of CIDP.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology
The CIDP symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total diagnosed prevalent cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients 7MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted CIDP symptoms epidemiology segmented as the Total prevalence of CIDP, Gender-Specific cases of CIDP, Clinical Subtype specific cases of CIDP, Age-Specific cases of CIDP. The report includes the prevalent scenario of CIDP symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology

The epidemiology segment also provides the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of CIDP in 7MM countries was estimated to be 44,700 in 2017.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Chapters
Drug chapter segment of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report encloses the detailed analysis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

Privigen: CSL Behring

Privigen is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment. Privigen is the first and only, ready-to-use, sterile, room-temperature stored, liquid, polyvalent IVIG stabilized with L-proline. The drug acts as an immunostimulant. It is approved in the US, Europe, and Japan for the treatment of CIDP in adults to improve neuromuscular disability and impairment.

Products detail in the report…

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Drugs

GGS-CIDP: Teijin Pharma

GGS-CIDP is an intravenous, freeze-dried sulfonated human normal immunoglobulin which reported to shows high efficacy in restoring the lost muscle strength by its immune regulatory action of inhibiting the inflammation of the peripheral nerves; the drug thus offers promise as a treatment that will restore lost muscle strength. The molecule has completed the Phase III developmental studies for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and filed NDA for manufacturing and marketing approval of GGS-CIDP.

Products detail in the report…

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in 7MM is expected to change in the study period 2017–2030.

The current therapeutic landscape in the 7MM divided into conventional therapies such as Corticosteroids, Plasma Exchange (PE), and Intravenous immunoglobulin (IVIG) which are also considered as the first line of therapy. In Corticosteroids therapy, mostly Prednisone and Dexamethasone are indicated among them. It induces a therapeutic response after 2 months and maximal improvement is observed after a long period with gradual incremental of dose. It has been in the therapeutic use for CIDP as of the first reporting of cases.

Plasma Exchange (PE) is an invasive therapy that requires well-trained personnel at specialized centers. It demonstrated short-term efficacy in the early days formerly may deteriorate within weeks to months after treatment.

Intravenous immunoglobulin (IVIG) has been used as the first-line therapy for CIDP over the past two decades with established efficacy and recommended to be offered as the long-term treatment. Though, the therapy with IVIG is expensive and time-consuming, and may have limited availability in some circumstances; the patient reported Improvement usually within a few weeks.

Key Findings

This section includes a glimpse of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in 7MM. The market size of CIDP in the seven major markets is expected to be USD 968 million in 2017.

The United States Market Outlook

This section provides the total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market Size and market Size by therapies in the United States.

The United States accounts for the highest market size of CIDP in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. Even though the IVIG has proven efficacy, the therapies are associated with the high cost and frequent adverse effects.

EU-5 Countries: Market Outlook

The total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market Size and market Size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Currently, used IVIG products are licensed for CIDP either purely nationally or via the MR-procedure in certain EU states or, in one case, centrally in the entire EU. The Tegeline of the LFB has been got approval from the France authorities. The Polyvalent immunoglobulins of the Kedrion Biopharma were approved by the Italian authorities to include in the CIDP treatment regimens. The approval of the SCIG paved the way for patient compliance therapies shortly. Consequently, the market share is expected to increase during the forecast period [2020–2030]

Japan Market Outlook

The total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size and market size by therapies in Japan is also mentioned.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) key players involved in developing targeted therapeutics.

Major players include Teijin Pharma, Octapharma, Shire/ Takeda, MedDay Pharmaceuticals, UCB Biopharma, argenx, Momenta Pharmaceuticals, Pfizer and others. GGS-CIDP (Teijin Pharma), NewGam (Octapharm) and HyQvia (Shire/Takeda) are the late-stage immunoglobin therapies.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) emerging therapies.

Reimbursement Scenario in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Commercial insurance companies typically reimburse for IG to treat many diseases regardless of whether they are designated as FDA-approved for IG therapy. Medicare Part B will reimburse IG for most diagnosis codes in the physician office or hospital outpatient setting. Both Typical and Atypical CIDP are covered under the FDA approved (Diagnosis Code – 357.81) condition to get coverage for IG therapy.

KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
The report covers the descriptive overview of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market

Report Highlights
In the coming years, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Launch of emerging therapies will significantly impact the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Insights
Patient Population
Therapeutic Approaches
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Analysis
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Key Strengths
11 Years Forecast
7MM Coverage
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions
Market Insights:

What was the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market share (%) distribution in 2017 and how it would look like in 2030?
What would be the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size during the forecast period (2017-2030)?
At what CAGR, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is expected to grow in 7MM during the forecast period (2017-2030)?
What would be the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market outlook across the 7MM during the forecast period (2017-2030)?
What would be the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
What is the historical Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
Out of all 7MM countries, which country would have the highest prevalent population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) during the forecast period (2017-2030)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
What are the current options for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the USA, Europe, and Japan?
What are the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
How many therapies are developed by each company for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment?
How many are emerging therapies in mid-stage, and late stage of development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment?
What are the key collaborations (Industry – Industry, Industry – Academia), Mergers and acquisitions, licensing activities related to the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and their status?
What are the key designations that have been granted for the emerging therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
What are the global historical and forecasted market of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
To understand the future market competition in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
To understand the future market competition in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market

What is Chronic Inflammatory Demyelinating Polyneuropathy?

Chronic inflammatory demyelinating polyneuropathy is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms mainly caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves

What was the market size of Chronic Inflammatory Demyelinating Polyneuropathy in 2017?

Market Size of Chronic inflammatory demyelinating polyneuropathy in the 7MM was found to be 1194.55 Million in 2017

What are the Chronic Inflammatory Demyelinating Polyneuropathy market drivers?

Rising Prevalence and Awareness, Advanced Technologies, Increasing R&D Activities are the Chronic Inflammatory Demyelinating Polyneuropathy market drivers

What are the Chronic Inflammatory Demyelinating Polyneuropathy market barriers?

Lack of awareness and Drug Pricing are the Chronic Inflammatory Demyelinating Polyneuropathy market barriers

Which companies are developing drugs for Chronic Inflammatory Demyelinating Polyneuropathy?

Teijin Pharma, OctaPharma, Shire, Takeda are developing drugs for Chronic Inflammatory Demyelinating Polyneuropathy

【レポートの目次】

1. Key Insights

2. Executive summary

3. Methodology

4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Overview at a Glance

4.1. Total Market Share (%) Distribution of CIDP in 2017

4.2. Total Market Share (%) Distribution of CIDP in 2030

5. Chronic inflammatory demyelinating polyneuropathy (CIDP): Disease Background and Overview

5.1. Introduction

5.2. Classification

5.3. Clinical Presentation

5.4. CIDP versus Guillain-Barre Syndrome

5.4.1. Disease course

5.5. Disease associations with CIDP

5.6. Pathogenesis of CIDP

5.6.1. FcRN role in the CIDP

5.7. Diagnosis

5.7.1. Diagnostic criteria

5.7.2. Differential diagnosis

5.7.3. AAN electrodiagnostic criteria

5.7.4. Koski et al’s criteria

5.7.5. European Federation of Neurological Societies and the Peripheral Nerve Society

6. Organizations

7. Epidemiology and Patient Population

7.1. Key Findings

8. Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM

9. United States Epidemiology

9.1. Assumptions and Rationale

9.2. Total Prevalent Population of CIDP in the United States

9.3. Gender-Specific Prevalent Population of CIDP in the United States

9.4. Clinical Subtype based Diagnosed cases of CIDP in the United States

9.5. Age-Specific Prevalent Population of CIDP in the United States

10. EU5 Epidemiology

10.1. Germany Epidemiology

10.1.1. Assumptions and Rationale

10.1.2. Total Prevalent Population of CIDP in Germany

10.1.3. Gender-Specific Prevalent Population of CIDP in Germany

10.1.4. Clinical Subtype based on Diagnosed cases of CIDP in Germany

10.1.5. Age-Specific Prevalent Population of CIDP in Germany

10.2. France Epidemiology

10.2.1. Assumptions and rationale

10.2.2. Total Prevalent Population of CIDP in France

10.2.3. Gender-Specific Prevalent Population of CIDP in France

10.2.4. Clinical Subtype based on Diagnosed cases of CIDP in France

10.2.5. Age-Specific Prevalent Population of CIDP in France

10.3. Italy Epidemiology

10.3.1. Assumptions and Rationale

10.3.2. Total Prevalent Population of CIDP in Italy

10.3.3. Gender-Specific Prevalent Population of CIDP in Italy

10.3.4. Clinical Subtype based on Diagnosed cases of CIDP in Italy

10.3.5. Age-Specific Prevalent Population of CIDP in Italy

10.4. Spain Epidemiology

10.4.1. Assumptions and Rationale

10.4.2. Total Prevalent Population of CIDP in Spain

10.4.3. Gender-Specific Prevalent Population of CIDP in Spain

10.4.4. Clinical Subtype based on Diagnosed cases of CIDP in Spain

10.4.5. Age-Specific Prevalent Population of CIDP in Spain

10.5. United Kingdom Epidemiology

10.5.1. Assumptions and Rationale

10.5.2. Total Prevalent Population of CIDP in the UK

10.5.3. Gender-Specific Prevalent Population of CIDP in the UK

10.5.4. Clinical Subtype based Diagnosed cases of CIDP in the UK

10.5.5. Age-Specific Prevalent Population of CIDP in the UK

10.6. Japan Epidemiology

10.6.1. Assumptions and Rationale

10.6.2. Total Prevalent Population of CIDP in Japan

10.6.3. Gender-Specific Prevalent Population of CIDP in Japan

10.6.4. Clinical Subtype based on Diagnosed cases of CIDP in Japan

10.6.5. Age-Specific Prevalent Population of CIDP in Japan

11. Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

11.1. Biological Activity of Available Treatments

11.2. EFNS/PNS Guideline on the management of CIDP

11.3. American Academy of Neurology (AAN) – CIDP Evidence-based guidelines

11.4. Treatment of CIDP – Cochrane systematic review

12. Treatment Algorithm

13. Unmet Needs

14. Marketed drugs

14.1. Privigen: CSL Behring

14.1.1. Drug Description

14.1.2. Regulatory Milestones

14.1.3. Other Developmental Activities

14.1.4. Safety and Efficacy

14.1.5. Product Profile

14.2. Hizentra: CSL Behring

14.2.1. Product Description

14.2.2. Regulatory Milestones

14.2.3. Other Development Activities

14.2.4. Safety and Efficacy

14.2.5. Product Profile

14.3. Gamunex-C: Grifols/Kedrion Biopharma

14.3.1. Product Description

14.3.2. Regulatory Milestones

14.3.3. Other Development Activities

14.3.4. Safety and Efficacy

14.3.5. Product Profile

14.4. Kenketsu Glovenin-I: Nihon Pharmaceutical

14.4.1. Product Description

14.4.2. Regulatory Milestones

14.4.3. Safety and Efficacy

14.4.4. Product Profile

14.5. Tegeline: LFB

14.5.1. Product Description

14.5.2. Regulatory Milestones

14.5.3. Product Profile

15. Emerging Therapies

15.1. Key Cross Competition

15.2. GGS-CIDP: Teijin Pharma

15.2.1. Drug Description

15.2.2. Other Developmental Activities

15.2.3. Clinical Development

15.2.4. Safety and Efficacy

15.2.5. Product Profile

15.3. NewGam: OctaPharma

15.3.1. Product Description

15.3.2. Clinical Development

15.3.3. Product Profile

15.4. HyQvia: Shire/ Takeda

15.4.1. Product Description

15.4.2. Other Developmental Activities

15.4.3. Clinical Development

15.4.4. Product Profile

15.5. Rozanolixizumab: UCB Biopharma

15.5.1. Product Description

15.5.2. Clinical Development

15.5.3. Safety and Efficacy

15.5.4. Product Profile

15.6. MD-1003: MedDay Pharmaceuticals

15.6.1. Drug Description

15.6.2. Other Developmental Activities

15.6.3. Clinical Development

15.6.4. Product Profile

15.7. Other potential therapies

15.8. I10E: LFB

15.8.1. Drug Description

15.8.2. Other Developmental Activities

15.8.3. Clinical Development

15.8.4. Product Profile

15.9. GNbAC1: GeNeuro Pharmaceuticals

15.9.1. Drug Description

15.9.2. Other Developmental Activities

15.9.3. Clinical Development

15.9.4. Safety and Efficacy

15.9.5. Product Profile

15.10. PF-06755347: Pfizer

15.10.1. Drug Description

15.10.2. Other Developmental Activities

15.10.3. Clinical Development

15.10.4. Product Profile

15.11. Efgartigimod: argenx

15.11.1. Drug Description

15.11.2. Clinical Development

15.11.3. Product Profile

15.12. M254: Momenta Pharmaceuticals

15.12.1. Drug Description

15.12.2. Other Developmental Activities

15.12.3. Product Profile

16. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): 7MM Market Analysis

16.1. Key Findings

16.2. Market Size of CIDP in 7MM

17. United States: Market Outlook

17.1. United States Market Size

17.1.1. The total market size of CIDP

17.1.2. Market Size of CIDP by therapy in the US

18. EU-5 countries: Market Outlook

18.1. Germany Market Size

18.1.1. The total market size of CIDP

18.1.2. Market Size of CIDP by Emerging therapy in Germany

18.2. France Market Size

18.2.1. The total market size of CIDP

18.2.2. Market Size of CIDP by Emerging therapy in France

18.3. Italy Market Size

18.3.1. The total market size of CIDP

18.3.2. Market Size of CIDP by Emerging therapy in Italy

18.4. Spain Market Size

18.4.1. The total market size of CIDP

18.4.2. Market Size of CIDP by Emerging therapy in Spain

18.5. United Kingdom Market Size

18.5.1. The total market size of CIDP

18.5.2. Market Size of CIDP by Emerging therapy in the UK

19. Japan Market Outlook

19.1. Japan Market Size

19.1.1. The total market size of CIDP

19.1.2. Market Size of CIDP by Emerging therapy in Japan

20. Market Drivers

21. Market Barriers

22. Case Studies

22.1.1. A Case Report of CIDP presented with unilateral ptosis

22.1.2. A Case Report of Electrophysiological responsiveness to long-term therapy in CIDP

23. Reimbursement policies

23.1. Access and Reimbursement Overview for Current and Future Therapies

23.1.1. Current Therapies

23.1.2. Future Therapies

24. SWOT Analysis

25. KOL Views

26. Appendix

26.1. Report Methodology

27. DelveInsight Capabilities

28. Disclaimer

29. About DelveInsight

Table 1: Major phenotypic variants of CIDP

Table 2: Clinical subtypes of chronic inflammatory demyelinating polyneuropathy

Table 3: Comparison of CIDP and subtypes

Table 4: Contrast of CIDP and Guillain Barre Syndrome

Table 5: Differential Diagnosis

Table 6: American Academy of Neurology Ad Hoc Subcommittee - electrodiagnostic criteria

Table 7: Koski et al’s criteria for chronic inflammatory demyelinating polyneuropathy (CIDP)

Table 8: Investigations to be considered

Table 9: EFNS/PNS Diagnostic Criteria for CIDP

Table 10: Total Prevalent Population of CIDP in the 7MM (2017-2030)

Table 11: Total Prevalent Population of CIDP in the US (2017-2030)

Table 12: Gender-Specific Prevalence of CIDP in the US (2017-2030)

Table 13: Clinical Subtype based Diagnosed cases of CIDP in the US (2017-2030)

Table 14: Age-Specific Prevalence of CIDP in the US (2017-2030)

Table 15: Total Prevalent Population of CIDP in Germany (2017-2030)

Table 16: Gender-Specific Prevalence of CIDP in Germany (2017-2030)

Table 17: Clinical Subtype based Diagnosed cases of CIDP in Germany (2017-2030)

Table 18: Age-Specific Prevalence of CIDP in Germany (2017-2030)

Table 19: Total Prevalent Population of CIDP in France (2017-2030)

Table 20: Gender-Specific Prevalence of CIDP in France (2017-2030)

Table 21: Clinical Subtype based Diagnosed cases of CIDP in France (2017-2030)

Table 22: Age-Specific Prevalence of CIDP in France(2017-2030)

Table 23: Total Prevalent Population of CIDP in Italy (2017-2030)

Table 24: Gender-Specific Prevalence of CIDP in Italy (2017-2030)

Table 25: Clinical Subtype based Diagnosed cases of CIDP in Italy (2017-2030)

Table 26: Age-Specific Prevalence of CIDP in Italy (2017-2030)

Table 27: Total Prevalent Population of CIDP in Spain (2017-2030)

Table 28: Gender-Specific Prevalence of CIDP in Spain (2017-2030)

Table 29: Clinical Subtype based Diagnosed cases of CIDP in Spain (2017-2030)

Table 30: Age-Specific Prevalence of CIDP in Spain (2017-2030)

Table 31: Total Prevalent Population of CIDP in the UK (2017-2030)

Table 32: Gender-Specific Prevalence of CIDP in the UK (2017-2030)

Table 33: Clinical Subtype based Diagnosed cases of CIDP in the UK (2017-2030)

Table 34: Age-Specific Prevalence of CIDP in the UK (2017-2030)

Table 35: Total Prevalent Population of CIDP in Japan (2017-2030)

Table 36: Gender-Specific Prevalence of CIDP in Japan (2017-2030)

Table 37: Clinical Subtype based Diagnosed cases of CIDP in Japan (2017-2030)

Table 38: Age-Specific Prevalence of CIDP in Japan (2017-2030)

Table 39: Recommendations for treatment

Table 40: An Evidence classification scheme for a therapeutic intervention

Table 41: Emerging Drugs Analysis

Table 42: GGS-CIDP, Clinical Trial Description, 2020

Table 43: NewGam, Clinical Trial Description, 2020

Table 44: HyQvia, Clinical Trial Description, 2020

Table 45: Rozanolixizumab, Clinical Trial Description, 2020

Table 46: MD-1003, Clinical Trial Description, 2020

Table 47: I10E, Clinical Trial Description, 2020

Table 48: PF-06755347, Clinical Trial Description, 2020

Table 49: Efgartigimod, Clinical Trial Description, 2020

Table 50: Market Size of CIDP in 7MM in USD Million (2017-2030)

Table 51: The US Market Size of CIDP in USD Million (2017-2030)

Table 52: Market Size of CIDP by therapies in the US in USD Million (2017-2030)

Table 53: Germany Market Size of CIDP in USD Million (2017-2030)

Table 54: Market Size of CIDP by therapies in Germany in USD Million (2017-2030)

Table 55: France Market Size of CIDP in USD Million (2017-2030)

Table 56: Market Size of CIDP by therapies in France in USD Million (2017-2030)

Table 57: Italy Market Size of CIDP in USD Million (2017-2030)

Table 58: Market Size of CIDP by therapies in Italy in USD Million (2017-2030)

Table 59: Spain Market Size of CIDP in USD Million (2017-2030)

Table 60: Market Size of CIDP by therapies in Spain in USD Million (2017-2030)

Table 61: UK Market Size of CIDP in USD Million (2017-2030)

Table 62: Market Size of CIDP by therapies in the UK in USD Million (2017-2030)

Table 63: Japan Market Size of CIDP in USD Million (2017-2030)

Table 64: Market Size of CIDP by therapies in Japan in USD Million (2017-2030)


List of Figures:

Figure 1: Schematic presentation of the distribution of demyelinating lesions

Figure 2: Immunopathogenesis of Chronic Inflammatory Demyelinating Neuropathy

Figure 3: Immunopathogenesis of Chronic Inflammatory Demyelinating Neuropathy

Figure 4: Algorithm of Diagnostic procedures

Figure 5: Total Prevalent Population of CIDP in the 7MM (2017-2030)

Figure 6: Total Prevalent Population of CIDP in the US (2017-2030)

Figure 7: Gender-Specific Prevalence of CIDP in the US (2017-2030)

Figure 8: Clinical Subtype based Diagnosed cases of CIDP in the US (2017-2030)

Figure 9: Age-Specific Prevalence of CIDP in the US (2017-2030)

Figure 10: Total Prevalent Population of CIDP in Germany (2017-2030)

Figure 11: Gender-Specific Prevalence of CIDP in Germany (2017-2030)

Figure 12: Clinical Subtype based Diagnosed cases of CIDP in Germany (2017-2030)

Figure 13: Age-Specific Prevalence of CIDP in Germany (2017-2030)

Figure 14: Total Prevalent Population of CIDP in France (2017-2030)

Figure 15: Gender-Specific Prevalence of CIDP in France (2017-2030)

Figure 16: Clinical Subtype based Diagnosed cases of CIDP in France (2017-2030)

Figure 17: Age-Specific Prevalence of CIDP in France (2017-2030)

Figure 18: Total Prevalent Population of CIDP in Italy (2017-2030)

Figure 19: Gender-Specific Prevalence of CIDP in Italy (2017-2030)

Figure 20: Clinical Subtype based Diagnosed cases of CIDP in Italy (2017-2030)

Figure 21: Age-Specific Prevalence of CIDP in Italy (2017-2030)

Figure 22: Total Prevalent Population of CIDP in Spain (2017-2030)

Figure 23: Gender-Specific Prevalence of CIDP in Spain (2017-2030)

Figure 24: Clinical Subtype based Diagnosed cases of CIDP in Spain (2017-2030)

Figure 25: Age-Specific Prevalence of CIDP in Spain (2017-2030)

Figure 26: Total Prevalent Population of CIDP in the UK (2017-2030)

Figure 27: Gender-Specific Prevalence of CIDP in the UK (2017-2030)

Figure 28: Clinical Subtype based Diagnosed cases of CIDP in the UK (2017-2030)

Figure 29: Age-Specific Prevalence of CIDP in the UK (2017-2030)

Figure 30: Total Prevalent Population of CIDP in Japan (2017-2030)

Figure 31: Gender-Specific Prevalence of CIDP in Japan (2017-2030)

Figure 32: Clinical Subtype based Diagnosed cases of CIDP in Japan (2017-2030)

Figure 33: Age-Specific Prevalence of CIDP in Japan (2017-2030)

Figure 34: Treatment Algorithm for CIDP

Figure 35: Unmet Needs of CIDP

Figure 36: Market Size of CIDP in the 7MM in USD Million (2017-2030)

Figure 37: Market Size of CIDP in the US, USD Millions (2017-2030)

Figure 38: Market Size of CIDP by therapies in the United States in USD Million (2017-2030)

Figure 39: Market Size of CIDP in Germany, USD Millions (2017-2030)

Figure 40: Market Size of CIDP by therapies in Germany in USD Million (2017-2030)

Figure 41: Market Size of CIDP in France, USD Millions (2017-2030)

Figure 42: Market Size of CIDP by therapies in France in USD Million (2017-2030)

Figure 43: Market Size of CIDP in Italy, USD Millions (2017-2030)

Figure 44: Market Size of by therapies in Italy in USD Million (2017-2030)

Figure 45: Market Size of CIDP in USD Million (2017-2030)

Figure 46: Market Size of CIDP by therapies in Spain in USD Million (2017-2030)

Figure 47: Market Size of CIDP in the UK, USD Millions (2017-2030)

Figure 48: Market Size of CIDP by therapies in the UK in USD Million (2017-2030)

Figure 49: Market Size of CIDP in Japan, USD Millions (2017-2030)

Figure 50: Market Size of CIDP by therapies in Japan in USD Million (2017-2030)

Figure 51: Market Drivers

Figure 52:Market Barriers

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[慢性炎症性脱髄性多発ニューロパシー(CIDP)治療薬の世界市場:インサイト・疫学・市場予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆